Physician profile
William C Cromwell
NPI 1699777565
$878,704.48
in general payments reported to CMS, 2019-2025
15 companies · $50K in 2025
The $50K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227K · 2020: $133K · 2021: $210K · 2022: $95K · 2023: $84K · 2024: $79K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $167K · Travel and Lodging: $33K · Consulting Fee: $7,543 · Food and Beverage: $5,979 · Education: $18.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $166,684.00 |
| Travel and Lodging | $32,947.66 |
| Consulting Fee | $7,543.00 |
| Food and Beverage | $5,978.73 |
| Education | $18.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $328,715.54 | 2020-2024 | Nexletol, Nexlizet |
| Amgen INC. | $298,234.17 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $236,656.23 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $6,206.22 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $3,536.08 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $3,248.60 | 2023-2024 | |
| Modernatx, INC. | $1,686.76 | 2024 | |
| Agepha Pharma Fz LLC | $182.58 | 2024 | Lodoco |
| Astrazeneca Uk Limited | $135.00 | 2025 | |
| Boston Scientific Corporation | $58.07 | 2025 | Artisan |
| Regeneron Healthcare Solutions, INC. | $31.44 | 2019-2023 | Evkeeza |
| Kowa Pharmaceuticals America, INC. | $13.79 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cromwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.